242 related articles for article (PubMed ID: 28922781)
1. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
Goldvaser H; Barnes TA; Šeruga B; Cescon DW; Ocaña A; Ribnikar D; Amir E
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922781
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
4. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
Reinhorn D; Yerushalmi R; Moore A; Desnoyers A; Saleh RR; Amir E; Goldvaser H
Breast Cancer Res Treat; 2020 Jul; 182(2):259-266. PubMed ID: 32488391
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis.
Zhao F; Ren D; Shen G; Ahmad R; Dong L; Du F; Zhao J
Crit Rev Oncol Hematol; 2020 Dec; 156():103114. PubMed ID: 33045493
[TBL] [Abstract][Full Text] [Related]
6. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Ingle JN
Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L
Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966
[TBL] [Abstract][Full Text] [Related]
8. Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials.
Xu L; Zhang Z; Xiang Q; Liu Q; Duan X; Liu Y; Cui Y
Clin Breast Cancer; 2019 Oct; 19(5):e578-e588. PubMed ID: 31257015
[TBL] [Abstract][Full Text] [Related]
9. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Cuppone F; Bria E; Verma S; Pritchard KI; Gandhi S; Carlini P; Milella M; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2008 Jan; 112(2):260-7. PubMed ID: 18041059
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis.
Goldvaser H; AlGorashi I; Ribnikar D; Seruga B; Templeton AJ; Ocana A; Amir E
Cancer Treat Rev; 2017 Nov; 60():53-59. PubMed ID: 28881223
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
[TBL] [Abstract][Full Text] [Related]
13. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.
Lee YK; Lee EG; Kim HY; Lee Y; Lee SM; Suh DC; Yoo JI; Lee S
J Korean Med Sci; 2020 Nov; 35(46):e403. PubMed ID: 33258332
[TBL] [Abstract][Full Text] [Related]
14. Risk-reducing medications for primary breast cancer: a network meta-analysis.
Mocellin S; Goodwin A; Pasquali S
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012191. PubMed ID: 31032883
[TBL] [Abstract][Full Text] [Related]
15. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
16. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
18. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
19. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
Khosrow-Khavar F; Yin H; Barkun A; Bouganim N; Azoulay L
Ann Oncol; 2018 Mar; 29(3):744-748. PubMed ID: 29293897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
